Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
NCT05050162
Recruiting
This phase II/III trial compares whether cisplatin given weekly with radiation therapy is better tolerated than cisplatin given every three weeks with radiation therapy for the treatment of head and neck cancer that has spread to other places in the body (advanced). The second part of this study will also help to find out if the cisplatin given weekly approach will extend patients' life by at least the same amount of time as the cisplatin given every three weeks approach. Cisplatin is in a class... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Mobile Infirmary Medical Center, Mobile, Alabama +365 locations
Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Register for Updates
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NCT05053152
Recruiting
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cel... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona +221 locations
Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma
Register for Updates
Linkage, Empowerment, and Access to Prevent Hypertension
NCT05061108
Recruiting
Brief Summary: Black adults have a higher incidence of hypertension (HTN) and a greater risk of HTN-related cardiovascular disease (CVD) compared with White adults. Even mild elevations in blood (BP) above 115/75 mm Hg are associated with increased CVD risk. Accordingly, emphasis is being placed on early interventions for high BP, particularly in those who are low cardiovascular risk(systolic BP 110-139 and diastolic BP \< 90 mm Hg), for participants lifestyle modification is recommended. Altho... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Wayne Health Mobile Units, Detroit, Michigan
Conditions: Hypertension, Blood Pressure, Cardiovascular Disease Other
Register for Updates
Amygdala Memory Enhancement
NCT05065450
Recruiting
The objective is to understand how amygdala activation affects other medial temporal lobe structures to prioritize long-term memories. The project is relevant to disorders of memory and to disorders involving affect and memory, including traumatic brain injury and post-traumatic stress disorder.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/14/2025
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Brain Diseases, Epilepsy, Memory Disorders, Traumatic Brain Injury, Cognitive Impairment, Post Traumatic Stress Disorder
Register for Updates
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376
Recruiting
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomusti... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/14/2025
Locations: Fairbanks Memorial Hospital, Fairbanks, Alaska +398 locations
Conditions: Glioblastoma, Gliosarcoma
Register for Updates
A Trial of Two-Week Brain Stimulation for Teenagers With ADHD
NCT05102864
Recruiting
The objective of this clinical trial is to examine whether non-invasive brain stimulation can modulate dysfunctional brain dynamics underlying adolescent ADHD to subsequently improve clinical symptoms.
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
07/14/2025
Locations: E. P. Bradley Hospital, East Providence, Rhode Island
Conditions: ADHD
Register for Updates
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
NCT05106296
Recruiting
Recent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tumor-associated antigen-presenting cells. The central clinical hypothesis for the GCC2020 study is that combining ibrutinib (BTK-inhibitor) with indoximod (IDO-inhibitor) during chemotherapy will synergistically enhance anti-tumor immune responses, leading to improvement in clinical response with manageable overlapping toxicity. GCC2020 is... Read More
Gender:
ALL
Ages:
Between 6 years and 25 years
Trial Updated:
07/14/2025
Locations: Augusta University, Georgia Cancer Center, Augusta, Georgia
Conditions: Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain Tumor
Register for Updates
Feasibility, Acceptability, and Preliminary Efficacy of a Novel Personalized Mobile Intervention for Suicide - Open Trial (2)
NCT05180344
Recruiting
The primary aim of this grant is to conduct pilot testing on a novel personalized mobile intervention for suicide - Mobile Application to Prevent Suicide (MAPS) - and to establish feasibility, acceptability, safety, and primary outcomes (i.e., suicidal ideation and behavior; re-hospitalization).
Gender:
ALL
Ages:
Between 18 years and 26 years
Trial Updated:
07/14/2025
Locations: Butler Hospital, Providence, Rhode Island
Conditions: Suicide, Suicide and Self-harm, Suicide, Attempted, Suicidal Ideation
Register for Updates
A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatment
NCT05189223
Recruiting
The US Veteran community continues to feel the impact of the overdose crisis, and opioid use disorder (OUD) diagnoses among Veterans continue to rise. Medication treatment (e.g., buprenorphine, methadone, naltrexone) helps prevent relapse and reduce overdose risk, but does not help with the psychological, social, and functional challenges of early recovery. Therapies that focus on interpersonal functioning and community integration may help improve quality of life during this high-risk period. T... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: VA Bedford HealthCare System, Bedford, MA, Bedford, Massachusetts
Conditions: Dependence, Opioid
Register for Updates
Examining Feasibility, Acceptability, and Sustainability of a Novel Personalized Smartphone Intervention for Suicide - Randomized Trial
NCT05202756
Recruiting
The primary aim of the present study is leverage existing infrastructure to develop novel technological features for a novel personalized smartphone intervention system, called the Mobile Application to Prevent Suicide (MAPS), and to establish feasibility, acceptability, safety, and estimate key parameters for primary outcomes (i.e., suicidal ideation and behavior; re-hospitalization), and target mechanisms.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/14/2025
Locations: Butler Hospital, Providence, Rhode Island +1 locations
Conditions: Suicide and Self-harm, Suicide, Suicide, Attempted, Suicidal Ideation
Register for Updates
Computer Monitor vs Augmented Reality 3MDR for PTSD PTSD: A Randomized Controlled Trial
NCT05244564
Recruiting
This is a prospective randomized controlled trial comparing two ways of delivering Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) therapy for posttraumatic stress disorder (PTSD). The study seeks 60 volunteers who have PTSD and are eligible for care in the Department of Defense healthcare system. There will be 10-14 therapy sessions that are 60-90 minutes long, about once a week, and symptoms will be assessed before and after the therapy as well as 3 and 6 month... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Uniformed Services University, Bethesda, Maryland
Conditions: Stress Disorders, Post-Traumatic
Register for Updates
Quantifying Bone and Skin Movement in the Residual Limb of Individuals With Transtibial Amputation Using Dynamic Stereo X-Ray
NCT05287646
Recruiting
Individuals with lower extremity amputation are often challenged by complications that arise from poor prosthetic fit, including movement of the residual limb in the socket, known as pistoning. Pistoning can lead to gait instability, skin problems, and pain. Different prosthetic suspension systems have been developed to decrease this motion, including elevated vacuum suspension, which utilizes a pump to draw air from the socket. However, scientific analyses to understand the movement between the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: VA NY Harbor Healthcare System, New York, NY, New York, New York
Conditions: Amputation, Lower Limb
Register for Updates